Compare AbbVie Inc (ABBV) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Berkshire Hathaway Inc Class B — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Berkshire Hathaway Inc Class B trades at $499.79. The key difference: AbbVie Inc pays a 2.72% dividend while Berkshire Hathaway Inc Class B pays none, and AbbVie Inc is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| ABBV | BRK.B | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Financials |
52-Week High | $261.07 | $513.70 |
52-Week Low | $184.85 | $459.10 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
BRK.B trades at $500.02, down 1.32% today, with a bullish technical signal driven by moving averages. Analyst consensus is positive with 57% buy ratings. Key support lies at $499, while resistance is at $509. The stock's technical strength is supported by a high ADX indicating a strong trend.
The outlook for BRK.B is cautiously optimistic given strong analyst support and bullish technicals, but overbought RSI levels near 80 suggest potential near-term consolidation. Risks include market volatility and Berkshire Hathaway's exposure to economic cycles. Upside depends on continued earnings growth and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →
